Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 202 participants.

Also called NCT02657356

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 202 participants (enrolled count) (from the registry)
Sponsor
  • Biogen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02657356
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Germany, Israel, Japan, Mexico, Netherlands, Philippines, Spain, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02657356. Randomized; double masking; primary purpose treatment. Start 2016-10-04 (actual); primary completion 2020-05-07 (actual). Results posted on 2023-05-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST
Condition
Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
Intervention (Drug)
Placebo capsules
Intervention (Drug)
Bardoxolone methyl capsules
Lead sponsor
Biogen (class: industry)

Record details

Record id
cardio:ct-nct02657356
Content hash
8565148b2f96c693ead906a9353863dc45ea96e5c95a9a84239df0a6f76c1f83